What does CUSIP 74006W108 represent in this 13F holders report?

CUSIP 74006W108 is the security identifier for PRAX - PRAXIS PRECISION MEDICINES I - COM used to aggregate holder disclosures.

How many institutions held PRAX - PRAXIS PRECISION MEDICINES I - COM in Q1 2022?

99 institutional investors reported PRAX - PRAXIS PRECISION MEDICINES I - COM for Q1 2022. Use the holders table for investor-level position and value details.

PRAXIS PRECISION MEDICINES I - COM (PRAX)

CUSIP: 74006W108

Q1 2022 13F Holders as of 31 Mar 2022

Security type / class: Equity / COM
Total 13F shares: 45,371,167
Total 13F value: $463,393,666
Share change: +1,552,593
SEC-reported price per share: $10.21
Number of holders: 99
Value change: +$13,476,056
Number of buys: 49
Number of sells: 34

Security key

74006W108

Report period

Q1 2022

Institutions

Top holders

PRAX full security history Ownership snapshot Full 13F holder table Praxis Precision Medicines, Inc. SEC filings Praxis Precision Medicines, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PRAX - PRAXIS PRECISION MEDICINES I - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Clarus Lifesciences III, ...

Disclosed value leader

Clarus Lifesciences III, ...

Comparable rows

0/15

Latest evidence

31 Dec 2021

3/4/5 13F Highest disclosed value: $123,282,606 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Clarus Lifesciences III, L.P. has the largest disclosed position value at $123.28M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Clarus Lifesciences III, L.P.'s linked filing trail.

Disclosed position value Top 5

Clarus Lifesciences III, L.P. $123.28M

Blackstone Inc. $96.41M

FMR LLC $90.15M

EVENTIDE ASSET MANAGEMENT, LLC $75.07M

Janus Henderson Group Ltd. $65.86M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Clarus Lifesciences III, L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$123,282,606 4,894,109 shares	—	12 May 2021
Blackstone Inc.	13F Company 13F	— denominator unverified	$96,414,000 4,894,109 shares	—	31 Dec 2021
FMR LLC	13F Company 13F	— denominator unverified	$90,152,000 4,576,229 shares	—	31 Dec 2021
EVENTIDE ASSET MANAGEMENT, LLC	13F Company 13F	— denominator unverified	$75,069,000 3,810,599 shares	—	31 Dec 2021
Janus Henderson Group Ltd.	13F Company 13F	— denominator unverified	$65,863,000 3,342,569 shares	—	31 Dec 2021
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$64,861,000 3,292,443 shares	—	31 Dec 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

45,371,167

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Holder diff

Investor	Q1 2022 Shares	Q1 2022 Shares	Share Diff	Share Chg %	Q1 2022 value	Q1 2022 value	Value change	Value Chg %